Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:37:25 EDT Sat 12 Jul 2025
Enter Symbol
or Name
USA
CA



Q:CHRS - COHERUS ONCOLOGY INC - https://www.coherus.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CHRS - Q0.30.85·0.951.00.88+0.01281.51,684.51,3152,0360.87  0.9118  0.852.43  0.660319:23:35May 3015 min RT 2¢

Recent Trades - Last 10 of 2036
Time ETExPriceChangeVolume
19:23:35Q0.89830.03113,500
18:06:57Q0.89820.031200
17:41:28Q0.89830.03113
17:31:29Q0.87650.009325
17:16:32Q0.89820.0311
17:10:23Q0.890.0228500
16:36:15Q0.8662-0.0016
16:36:03Q0.8662-0.0016
16:22:28Q0.87650.009320
16:08:08Q0.8662-0.0011

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-30 08:00U:CHRSNews ReleaseCoherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
2025-05-27 08:30U:CHRSNews ReleaseCoherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI(TM) (toripalimab-tpzi)
2025-05-12 16:15U:CHRSNews ReleaseCoherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
2025-05-05 16:01U:CHRSNews ReleaseCoherus to Report First Quarter 2025 Financial Results on May 12, 2025
2025-05-01 17:04U:CHRSNews ReleaseCoherus to Participate in Upcoming Investor Conferences
2025-04-28 10:10U:CHRSNews ReleaseCoherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
2025-04-14 08:00U:CHRSNews ReleaseCoherus Completes Strategic Transformation with Successful Divestiture of UDENYCA(TM) Franchise
2025-04-01 08:01U:CHRSNews ReleaseCoherus Announces Repurchase of Approximately $170 Million of Convertible Notes
2025-03-25 16:30U:CHRSNews ReleaseCoherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
2025-03-10 16:13U:CHRSNews ReleaseCoherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
2025-03-03 08:30U:CHRSNews ReleaseCoherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
2025-02-24 09:08U:CHRSNews ReleaseCoherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
2025-01-22 07:00U:CHRSNews ReleaseCoherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
2025-01-08 08:00U:CHRSNews ReleaseCoherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-18 08:30U:CHRSNews ReleaseCoherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
2024-12-03 07:00U:CHRSNews ReleaseCoherus Announces Agreement to Divest UDENYCA(TM) Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
2024-11-27 16:01U:CHRSNews ReleaseCoherus Management to Participate in the 2024 Citi Global Healthcare Conference
2024-11-06 16:01U:CHRSNews ReleaseCoherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-10-30 16:20U:CHRSNews ReleaseCoherus to Report Third Quarter 2024 Financial Results on November 6, 2024
2024-08-08 16:05U:CHRSNews ReleaseCoherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update